Literature DB >> 12054059

Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia.

Kent Jardemark1, Marie-Louise Wadenberg, Pernilla Grillner, Torgny H Svensson.   

Abstract

The findings that dopamine D3 and D4 receptors are highly expressed in limbic and cortical areas (D4 more than D3), and the fact that the atypical drug clozapine has preferential affinity for the D4 receptors have suggested an involvement of these receptors in schizophrenia. Subsequently, many pharmaceutical companies have pursued the approach of developing selective dopamine D3 or D4 antagonists as potential antipsychotics. This review will discuss the current status of selective dopamine D3 and D4 receptor antagonists for the treatment of schizophrenia.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12054059

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  6 in total

1.  Endogenous dopamine (DA) competes with the binding of a radiolabeled D₃ receptor partial agonist in vivo: a positron emission tomography study.

Authors:  Robert H Mach; Zhude Tu; Jinbin Xu; Shihong Li; Lynne A Jones; Michelle Taylor; Robert R Luedtke; Colin P Derdeyn; Joel S Perlmutter; Mark A Mintun
Journal:  Synapse       Date:  2011-03-21       Impact factor: 2.562

2.  Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.

Authors:  Robert R Luedtke; Yogesh Mishra; Qi Wang; Suzy A Griffin; Cathy Bell-Horner; Michelle Taylor; Suwanna Vangveravong; Glenn H Dillon; Ren-Qi Huang; David E Reichert; Robert H Mach
Journal:  ACS Chem Neurosci       Date:  2012-10-12       Impact factor: 4.418

3.  Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626.

Authors:  Suwanna Vangveravong; Michelle Taylor; Jinbin Xu; Jinquan Cui; Wesley Calvin; Sonja Babic; Robert R Luedtke; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2010-05-24       Impact factor: 3.641

Review 4.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

5.  Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist.

Authors:  Jinbin Xu; Suwanna Vangveravong; Shihong Li; Jinda Fan; Lynne A Jones; Jinquan Cui; Ruike Wang; Zhude Tu; Wenhua Chu; Joel S Perlmutter; Robert H Mach
Journal:  Neuroimage       Date:  2013-01-17       Impact factor: 6.556

6.  Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways.

Authors:  Michelle Taylor; Peter Grundt; Suzy A Griffin; Amy Hauck Newman; Robert R Luedtke
Journal:  Synapse       Date:  2010-03       Impact factor: 2.562
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.